Loading
CAPTAIN-1st showed that adding the PD-1 antibody camrelizumab to gemcitabine and cisplatin kept advanced nasopharyngeal cancer under control for about three months longer, confirming with a second drug what JUPITER-02 found with toripalimab.
CAPTAIN-1st randomised 263 patients with untreated recurrent or metastatic nasopharyngeal carcinoma at 28 Chinese centres to camrelizumab or placebo with gemcitabine and cisplatin for up to six cycles, followed by camrelizumab or placebo maintenance. Gemcitabine-cisplatin had been the standard since the 2016 GEM20110714 trial.
Reported by Yunpeng Yang and Li Zhang in Lancet Oncology in 2021, median progression-free survival was 9.7 months with camrelizumab against 6.9 months with placebo (hazard ratio 0.54). Camrelizumab's characteristic reactive capillary haemangiomas were the main additional toxicity.
With JUPITER-02 (toripalimab) and RATIONALE-309 (tislelizumab), it made PD-1 blockade with gemcitabine-cisplatin the first-line standard for advanced nasopharyngeal carcinoma in China and in the NCCN guideline; camrelizumab was approved for this use in China in 2021.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
263 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Camrelizumab + gemcitabine-cisplatin | - | 9.7 months | 0.54 | - | - |
| Placebo + gemcitabine-cisplatin | - | 6.9 months |
Shares JUPITER-02, Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Gemcitabine, Cisplatin.
Shares JUPITER-02, Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin.
Shares Sun Yat-sen University Cancer Center, Nasopharyngeal carcinoma, Gemcitabine, Cisplatin.
Shares Sun Yat-sen University Cancer Center, Camrelizumab, PD-1, Head and neck squamous cell carcinoma.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Gemcitabine + cisplatin, Cisplatin.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Gemcitabine, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, PD-1, Immune checkpoint inhibitors.